health and business

Abstract: This article presents the findings of a randomised, double-blind, active-controlled trial known as the Ketamine for Treatment-Resistant Depression Study (KADS). The study aimed to evaluate the efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections in individuals with treatment-resistant depression. Introduction:  Treatment-resistant depression poses significant challenges in clinical psychiatry. Existing antidepressant therapies often yield limited results, necessitating the exploration of alternative treatment options. Ketamine, a glutamatergic N-methyl-D-aspartate receptor antagonist, has shown promise as a potential therapeutic intervention for treatment-resistant depression. This study aimed to assess the efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections in this patient population. Methods:  The KADS study employed a randomised, double-blind, active-controlled design to investigate the effects of rep...